prednisolone and Pneumococcal Infections studies

Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.

Pneumococcal Infections: Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.

Research Excerpts

Excerpt	Relevance	Reference
"To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both."	7.73	Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006)
" About two months before this admission the patient was diagnosed as Henoch-Schönlein purpura nephritis who was treated with 40 mg/day of prednisolone(PSL)."	3.74	[Infective endocarditis successfully treated by early medical therapy in a patient with Henoch-Schönlein purpura nephritis under oral steroid therapy]. ( Iwasaki, S; Nagayama, Y; Yamaguchi, H; Yoshimura, A, 2007)
"To compare antibody responses to 23-valent pneumococcal vaccine (Pneumovax) in controls and patients with established rheumatoid arthritis (RA) treated with TNF blockers, methotrexate (MTX) or a combination of both."	3.73	Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. ( Geborek, P; Jönsson, G; Kapetanovic, MC; Saxne, T; Sjöholm, A; Truedsson, L, 2006)
"Bacterial keratitis results in corneal scarring and subsequent visual impairment."	1.39	Improvement in corneal scarring following bacterial keratitis. ( Acharya, NR; Greninger, DA; Keenan, JD; Lietman, TM; Mascarenhas, J; McClintic, SM; Srinivasan, M, 2013)
"In rabbit models of untreated Pseudomonas keratitis and pneumococcal keratitis, topical 1% prednisolone phosphate, 0."	1.28	Topical anti-inflammatory agents in an animal model of microbial keratitis. ( Gritz, DC; Kwitko, S; Lee, TY; McDonnell, PJ, 1990)

Research

Studies (12)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Best Hard Contact Lens Corrected Visual Acuity Measured in logMAR, Correcting for Best Spectacle Corrected Visual Acuity at Enrollment

Timeframe	Studies, this research(%)	All Research%
pre-1990	5 (41.67)	18.7374
1990's	2 (16.67)	18.2507
2000's	2 (16.67)	29.6817
2010's	3 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Hafiji, J	1
Bhogal, B	1
Rytina, E	1
Burrows, NP	1
McClintic, SM	1
Srinivasan, M	2
Mascarenhas, J	1
Greninger, DA	1
Acharya, NR	2
Lietman, TM	2
Keenan, JD	1
Ray, KJ	1
Prajna, L	1
Geetha, M	1
Karpagam, R	1
Glidden, D	1
Oldenburg, CE	1
Sun, CQ	1
McLeod, SD	1
SCHEIBNER, M	1
MITCHELL, JH	1
Kapetanovic, MC	1
Saxne, T	1
Sjöholm, A	1
Truedsson, L	1
Jönsson, G	1
Geborek, P	1
Nagayama, Y	1
Iwasaki, S	1
Yamaguchi, H	1
Yoshimura, A	1
Isenberg, DA	1
Lipkin, DP	1
Mowbray, JF	1
Fisher, C	1
Davies, R	1
Wilcox, LD	1
De Rose, G	1
Cooke, D	1
Bates, AK	1
Kirkness, CM	1
Ficker, LA	1
Steele, AD	1
Rice, NS	1
Gritz, DC	1
Lee, TY	1
Kwitko, S	1
McDonnell, PJ	1
Kishimoto, M	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Steroids for Corneal Ulcers Trial[NCT00324168]	Phase 4	500 participants (Actual)	Interventional	2006-09-30	Completed
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.[NCT03762824]	Phase 4	300 participants (Actual)	Interventional	2016-06-14	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 3 months from enrollment

Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 12 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate

Intervention	logMAR (Mean)
Steroid	0.42
Placebo	0.41

LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 12 months from enrollment

Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR at 3 Months, Using Best Spectacle-corrected Enrollment Visual Acuity as a Co-variate

Intervention	logMAR (Mean)
Steroid	2.90
Placebo	2.87

LogMAR (logarithm of the Minimum Angle of Resolution) is a measure of visual acuity in which the smaller values indicate better visual acuity. (NCT00324168)
Timeframe: 3 months from enrollment

Best Spectacle-corrected Visual Acuity (BSCVA) in logMAR Using MIC (Minimum Inhibitory Concentration) to Moxifloxacin as a Covariate

Intervention	logMAR (Mean)
Steroid	0.48
Placebo	0.49

Best spectacle-corrected visual acuity (BSCVA) for this outcome is measured in logMAR (logarithm of the Minimum Angle of Resolution) in which smaller values indicate better visual acuity. Minimum inhibitory concentration (MIC) to moxifloxacin was measured by E test and a log2-transformation of MIC was used in all analyses. In this analysis we add MIC to the model examining BSCVA at 3 months. (NCT00324168)
Timeframe: 3 months after enrollment

Infiltrate/Scar Size, Correcting for Infiltrate/Scar Size at Enrollment

Ocular Perforations

Time to Resolution of Epithelial Defect

Intervention	logMAR (Mean)
Steroid	0.50
Placebo	0.46

Intervention	mm (Mean)
Steroid	3.07
Placebo	3.02

Intervention	participants (Number)
Steroid	7
Placebo	8

This outcome measured time from enrollment to resolution of the epithelial defect in days for up to 21 days. For three weeks patients were examined every 3 days for size of epithelial defect until the defect was gone. (NCT00324168)
Timeframe: From enrollment up to 21 days

Subgroup Analysis of Best Spectacle-corrected Visual Acuity (BSCVA) by Categories of Infiltrate Depth

Intervention	days (Mean)
Steroid	9.77
Placebo	9.43

BSCVA measured in logMAR will be examined by categories infiltrate depth (categorized by depth percentage) by mean and standard deviation as well as in a regression model. (NCT00324168)
Timeframe: 3 months from enrollment

Subgroup Analysis Predicting 3 Month Best Spectacle-corrected Visual Acuity (BSCVA) by Causative Organism

Intervention	logMAR (Mean)
	>0-33%	>33%-67%	>67%-100%
Placebo	0.26	0.47	0.86
Steroid	0.35	0.52	0.80

BSCVA measured in logMAR will be estimated by causative organism (either Nocardia spp, Streptococcus pneumoniae, Moraxella spp, or Pseudomonas aeruginosa). BSCVA will be examined for each causative organism by mean and standard deviation as well as in a regression model. (NCT00324168)
Timeframe: 3 months after enrollment

Subgroup Analysis Predicting 3 Month Best Spectacle-corrected Visual Acuity (BSCVA) by Visual Acuity Group

Intervention	logMAR (Mean)
	Nocardia spp	Streptococcus pneumoniae	Moraxella spp	Pseudomonas aeruginosa
Placebo	0.36	0.52	0.26	0.45
Steroid	0.54	0.49	0.46	0.53

Best spectacle-corrected visual acuity (BSCVA) for this subgroup analysis was measured in logMAR and then categorized by equivalent Snellen fractions (NCT00324168)
Timeframe: 3 months from enrollment

Subgroup Analysis Predicting Best Spectacle-corrected Visual Acuity (BSCVA) as Stratified by Categories of Infiltrate/Scar Size

Intervention	logMAR (Mean)
	<20/40	20/40 to 20/800	Counting fingers (CF) or worse
Placebo	-0.02	0.38	1.15
Steroid	0.06	0.36	1.00

Best-spectacle visual acuity (BSCVA) at 3 months from enrollment is stratified by categories of infiltrate/scar size and examined by treatment arm (NCT00324168)
Timeframe: 3 months from enrollment

Intervention	logMAR (Mean)
	0-1.90 mm	1.91-2.70 mm	2.71-4.06 mm	4.07-8.90 mm
Placebo	0.19	0.29	0.53	0.96
Steroid	0.18	0.39	0.53	0.85

Article	Year
Bullous pemphigoid in infancy developing after the first vaccination. Clinical and experimental dermatology, 2010, Volume: 35, Issue:8 Topics: Diphtheria; Glucocorticoids; Haemophilus Infections; Heptavalent Pneumococcal Conjugate Vaccine; Hum	2010
Improvement in corneal scarring following bacterial keratitis. Eye (London, England), 2013, Volume: 27, Issue:3 Topics: Adult; Aged; Aza Compounds; Cicatrix; Corneal Ulcer; Eye Infections, Bacterial; Female; Fluoroquinol	2013
[Intralumbar Solu-Dacortin treatment of severe pneumococcal meningitis]. Wiener klinische Wochenschrift, 1961, Apr-14, Volume: 73 Topics: Humans; Meningitis; Meningitis, Meningococcal; Meningitis, Pneumococcal; Pneumococcal Infections; Pr	1961
PNEUMOCOCCAL MENINGO-ENCEPHALITIS. AN UNUSUAL CASE. Postgraduate medical journal, 1964, Volume: 40 Topics: Ataxia; Body Image; Chloramphenicol; Encephalitis; Humans; Meningitis; Meningitis, Pneumococcal; Men	1964
Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford, England), 2006, Volume: 45, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibo	2006
[Infective endocarditis successfully treated by early medical therapy in a patient with Henoch-Schönlein purpura nephritis under oral steroid therapy]. Nihon Jinzo Gakkai shi, 2007, Volume: 49, Issue:4 Topics: Adult; Endocarditis, Bacterial; Humans; IgA Vasculitis; Male; Nephritis; Penicillin G; Pneumococcal	2007
Fatal pneumococcal epiglottitis in lupus overlap syndrome. Clinical rheumatology, 1984, Volume: 3, Issue:4 Topics: Adult; Epiglottitis; Female; Humans; Laryngitis; Lupus Erythematosus, Systemic; Myositis; Pneumococc	1984
Use of the dog spleen for studying effects of irradiation and chemotherapeutic agents, with suggested uses of other organs. Cancer, 1976, Volume: 38, Issue:1 Topics: Animals; Antineoplastic Agents; Azathioprine; Cyclophosphamide; Dogs; Fluorouracil; Leukocytes; Mech	1976
Microbial keratitis after penetrating keratoplasty. Eye (London, England), 1990, Volume: 4 ( Pt 1) Topics: Adult; Aged; Aged, 80 and over; Chloramphenicol; Female; Graft Rejection; Humans; Keratitis; Keratit	1990
Topical anti-inflammatory agents in an animal model of microbial keratitis. Archives of ophthalmology (Chicago, Ill. : 1960), 1990, Volume: 108, Issue:7 Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Flurbiprofen; Ke	1990
[Study on carbohydrate and insulin metabolism in experimental pneumococcal infections]. Nihon Naibunpi Gakkai zasshi, 1965, Oct-20, Volume: 41, Issue:7 Topics: Animals; Blood Protein Electrophoresis; Blood Proteins; Carbohydrate Metabolism; Diabetes Mellitus,	1965

prednisolone and Pneumococcal Infections